Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Nataša Dragašević-Mišković, Igor Petrović, Iva Stanković & Vladimir S. Kostić. (2019) Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients. Expert Opinion on Pharmacotherapy 20:2, pages 219-230.
Read now
Read now
Thomas Müller. (2017) Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson’s disease. Expert Opinion on Pharmacotherapy 18:14, pages 1457-1465.
Read now
Read now
D. Tripathy, J. Chakraborty & K. P. Mohanakumar. (2015) Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson's disease. Free Radical Research 49:9, pages 1129-1139.
Read now
Read now
Jenny Kim, Ellen Sidransky & Grisel Lopez. (2015) Understanding and managing parkinsonism in patients with glucocerebrosidase mutations. Expert Opinion on Orphan Drugs 3:5, pages 549-562.
Read now
Read now
Articles from other publishers (34)
Mohammad Ahmed Khan, Nafis Haider, Tanveer Singh, Ritam Bandopadhyay, Mohammed M. Ghoneim, Sultan Alshehri, Murtada Taha, Javed Ahmad & Awanish Mishra. (2023) Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research. Metabolic Brain Disease 38:3, pages 873-919.
Crossref
Crossref
Destany K. Kwon, Mohit Kwatra, Jing Wang & Han Seok Ko. (2022) Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies. Cells 11:23, pages 3736.
Crossref
Crossref
Zhirong Wan, Xuemei Wang, Huizi Ma, Zhan Wang & Tao Feng. (2022) Risk factors for motor complications in female patients with Parkinson’s disease. Neurological Sciences 43:8, pages 4735-4743.
Crossref
Crossref
Chunxiao Wu, Hongji Guo, Yingshan Xu, Luping Li, Xinyu Li, Chunzhi Tang, Dongfeng Chen & Meiling Zhu. (2022) The Comparative Efficacy of Non-ergot Dopamine Agonist and Potential Risk Factors for Motor Complications and Side Effects From NEDA Use in Early Parkinson's Disease: Evidence From Clinical Trials. Frontiers in Aging Neuroscience 14.
Crossref
Crossref
Rebecca M Gilbert. (2021) Update on Parkinson's Disease Therapy. Neurology 17:2, pages 92.
Crossref
Crossref
R. Depoortere, T.H. Johnston, S.H. Fox, J.M. Brotchie & A. Newman-Tancredi. (2020) The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques. Parkinsonism & Related Disorders 78, pages 151-157.
Crossref
Crossref
Xi Chen, Yuanyuan Wang, Haifeng Wu, Cheng Cheng & Weidong Le. (2020) Research advances on L-DOPA-induced dyskinesia: from animal models to human disease. Neurological Sciences 41:8, pages 2055-2065.
Crossref
Crossref
Etienne Goubault, Sarah Bogard, Pierre J. Blanchet, Erwan Bézard, Claude Vincent, Davide Martino, Justyna Sarna, Oury Monchi & Christian Duval. (2020) Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson’s Disease. Tremor and Other Hyperkinetic Movements 10:1.
Crossref
Crossref
Ria Fisher, Atsuko Hikima, Rebecca Morris, Michael J. Jackson, Sarah Rose, Mark A. Varney, Ronan Depoortere & Adrian Newman-Tancredi. (2020) The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets. Neuropharmacology 167, pages 107997.
Crossref
Crossref
Saumitra Sen Singh, Sachchida Nand Rai, Hareram Birla, Walia Zahra, Aaina Singh Rathore & Surya Pratap Singh. (2019) NF-κB-Mediated Neuroinflammation in Parkinson’s Disease and Potential Therapeutic Effect of Polyphenols. Neurotoxicity Research 37:3, pages 491-507.
Crossref
Crossref
Fabio Bello, Mario Giannella, Gianfabio Giorgioni, Alessandro Piergentili & Wilma Quaglia. (2019) Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease. Biomolecules 9:4, pages 142.
Crossref
Crossref
Verónica Cabreira, Patrício Soares-da-Silva & João Massano. (2019) Contemporary Options for the Management of Motor Complications in Parkinson’s Disease: Updated Clinical Review. Drugs 79:6, pages 593-608.
Crossref
Crossref
Louise Cummings. 2018. Speech and Language Therapy. Speech and Language Therapy.
Angelo Antonini & Bianca Nitu. (2018) Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. Journal of Neural Transmission 125:8, pages 1131-1135.
Crossref
Crossref
Hana You, Louise-Laure Mariani, Graziella Mangone, Delphine Le Febvre de Nailly, Fanny Charbonnier-Beaupel & Jean-Christophe Corvol. (2018) Molecular basis of dopamine replacement therapy and its side effects in Parkinson’s disease. Cell and Tissue Research 373:1, pages 111-135.
Crossref
Crossref
Satoko Koganemaru, Yusuke Mikami, Hitoshi Maezawa, Satoshi Ikeda, Katsunori Ikoma & Tatsuya Mima. (2018) Neurofeedback Control of the Human GABAergic System Using Non-invasive Brain Stimulation. Neuroscience 380, pages 38-48.
Crossref
Crossref
Aryun Kim, Young Eun Kim, Ji Young Yun, Han-Joon Kim, Hui-Jun Yang, Woong-Woo Lee, Chae Won Shin, Hyeyoung Park, Yu Jin Jung, Ahro Kim, Yoon Kim, Mihee Jang & Beomseok Jeon. (2018) Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial. Journal of Movement Disorders 11:2, pages 65-71.
Crossref
Crossref
Hyerim Kim, Xudong Wang & Peng Jin. (2018) Developing DNA methylation-based diagnostic biomarkers. Journal of Genetics and Genomics 45:2, pages 87-97.
Crossref
Crossref
Jeanette M. Metzger, Corinne A. Jones & Marina E. Emborg. 2018. Conn's Handbook of Models for Human Aging. Conn's Handbook of Models for Human Aging
617
639
.
Tanya Chotibut, Samantha Meadows, Ella A. Kasanga, Tamara McInnis, Mark A. Cantu, Christopher Bishop & Michael F. Salvatore. (2017)
Ceftriaxone reduces
L
-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model
. Movement Disorders 32:11, pages 1547-1556.
Crossref
Crossref
Juan-Juan Du & Sheng-Di Chen. (2017) Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease. Chinese Medical Journal 130:15, pages 1856-1866.
Crossref
Crossref
Joanna Schwenkgrub, Malgorzata Zaremba, Ilona Joniec-Maciejak, Agnieszka Cudna, Dagmara Mirowska-Guzel & Iwona Kurkowska-Jastrzębska. (2017) The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson’s disease. PLOS ONE 12:7, pages e0182019.
Crossref
Crossref
Philippe Huot, Véronique Sgambato-Faure, Susan H. Fox & Andrew C. McCreary. (2017) Serotonergic Approaches in Parkinson’s Disease: Translational Perspectives, an Update. ACS Chemical Neuroscience 8:5, pages 973-986.
Crossref
Crossref
Shengdi Chen, Piu Chan, Shenggang Sun, Haibo Chen, Baorong Zhang, Weidong Le, Chunfeng Liu, Guoguang Peng, Beisha Tang, Lijuan Wang, Yan Cheng, Ming Shao, Zhenguo Liu, Zhenfu Wang, Xiaochun Chen, Mingwei Wang, Xinhua Wan, Huifang Shang, Yiming Liu, Pingyi Xu, Jian Wang, Tao Feng, Xianwen Chen, Xingyue Hu, Anmu Xie & Qin Xiao. (2016) The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease. Translational Neurodegeneration 5:1.
Crossref
Crossref
Thomas Müller. (2016) Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective. Neurodegenerative Disease Management 6:5, pages 385-398.
Crossref
Crossref
Andrew C. McCreary, Mark A. Varney & Adrian Newman-Tancredi. (2016) The novel 5-HT 1A receptor agonist, NLX-112 reduces l -DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements. Neuropharmacology 105, pages 651-660.
Crossref
Crossref
Dhanya Vijayakumar & Joseph Jankovic. (2016) Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs 76:7, pages 759-777.
Crossref
Crossref
James A.G. Crispo, Allison W. Willis, Dylan P. Thibault, Yannick Fortin, Matthew Emons, Lise M. Bjerre, Dafna E. Kohen, Santiago Perez-Lloret, Donald Mattison & Daniel Krewski. (2016) Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson's Disease. Movement Disorders Clinical Practice 3:3, pages 257-267.
Crossref
Crossref
Angelo Antonini, Victor S. C. Fung, James T. Boyd, John T. Slevin, Coleen Hall, Krai Chatamra, Susan Eaton & Janet A. Benesh. (2016)
E
ffect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced
P
arkinson's disease patients
. Movement Disorders 31:4, pages 530-537.
Crossref
Crossref
Svetlana A. Ivanova & Anton J. M. Loonen. (2016) Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding. Parkinson's Disease 2016, pages 1-5.
Crossref
Crossref
Julie K. Andersen & Shankar Chinta. 2016. Advances in Geroscience. Advances in Geroscience
229
255
.
Peter Jenner. (2015) Treatment of the later stages of Parkinson’s disease – pharmacological approaches now and in the future. Translational Neurodegeneration 4:1.
Crossref
Crossref
Olivier Rascol, Santiago Perez-Lloret & Joaquim J Ferreira. (2015) New treatments for levodopa-induced motor complications. Movement Disorders 30:11, pages 1451-1460.
Crossref
Crossref
H. Iderberg, A.C. McCreary, M.A. Varney, M.S. Kleven, W. Koek, L. Bardin, R. Depoortère, M.A. Cenci & A. Newman-Tancredi. (2015) NLX-112, a novel 5-HT 1A receptor agonist for the treatment of l -DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat. Experimental Neurology 271, pages 335-350.
Crossref
Crossref